{"disease":{"id":"acute-bacterial-skin-and-skin-structure-infection","name":"acute bacterial skin and skin structure infection"},"drugs":{"marketed":[{"drug_id":"omadacycline-tosylate","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"delafloxacin","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"ceftaroline","indication_name":"Acute bacterial skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftaroline Fosamil","generic_name":"CEFTAROLINE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03137173","title":"Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":679,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true},{"nct_id":"NCT03405064","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"Wockhardt","has_results":false},{"nct_id":"NCT02961764","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04298463","title":"Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI","phase":"","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT05599295","title":"Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Melinta Therapeutics, LLC","has_results":false},{"nct_id":"NCT03873987","title":"Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Melinta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03176134","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03233438","title":"Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT06394518","title":"Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"TenNor Therapeutics Inc.","has_results":false},{"nct_id":"NCT03732365","title":"Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sonescence, Inc.","has_results":false},{"nct_id":"NCT02452918","title":"A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"The Medicines Company","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}